Allt inom Issuance
Nanexa carries out a rights issue of approximately SEK 121 million
Nanexa AB (publ) (”Nanexa” or the ”Company”) carries out an issue of shares of approximately SEK 121 million before transaction costs with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The board of directors resolved today, on September 21, 2023, on the Rights Issue on the basis of the authorisation from the annual general meeting on June 9, 2023. The Company has received subscription undertakings and guarantee commitments in a total amount of SEK 75 million, which corresponds to approximately 62 per cent of the Rights Issue. The purpose of the Rights Issue is to strengthen the Company’s financial position, to enable the planned clinical studies as well as carry out other value creating activities supporting PharmaShell and the NEX projects. As a consequence of the Rights Issue, the board of directors has resolved to delay the publication of the Company’s interim report for the period January – September 2023 until November 30, 2023.
Nanexa signs an exclusivity and evaluation agreement worth SEK 46.1 million and completes a directed share issue of SEK 17.2 million to Novo Nordisk
Nanexa AB (publ) (“Nanexa” or the “Company”) today announces that the Company has signed a Material Transfer and Feasibility Study Agreement (the “Evaluation Agreement”) with leading global pharmaceutical company Novo Nordisk A/S (”Novo Nordisk”) for the evaluation of Nanexa’s drug delivery system PharmaShell® with Novo Nordisk products. As part of the Evaluation Agreement, Nanexa will receive payments of approximately SEK 46.1 million for providing Novo Nordisk exclusivity and performing work under the Evaluation Agreement, whereof approximately SEK 41.7 million is an upfront payment at signing. In connection with the signing of the Evaluation Agreement, the board of directors of Nanexa also resolved, based on the authorisation granted by the annual general meeting held on 9 June 2022, to carry out a directed share issue to Novo Nordisk of 10,000,000 shares at a subscription price of SEK 1.72 per share (the “Directed Share Issue”) through which Nanexa raises gross proceeds of approximately SEK 17.2 million. The subscription price is equivalent to a premium of 33 percent versus the closing price yesterday for the Company’s shares. In total, Nanexa will thus receive approximately SEK 63.3 million from the Evaluation Agreement and the Directed Share Issue.